Related Experiment Video
Updated: Dec 24, 2025
07:32
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
1.8K
Interleukin-6 polymorphisms in HCC patients chronically infected with HCV
Faisal Adnan1, Najeeb Ullah Khan1, Aqib Iqbal1
11Institute of Biotechnology and Genetic Engineering (Health Division), The University of Agriculture, Peshawar, Pakistan.
Infectious Agents and Cancer
|April 9, 2020
Summary
Interleukin-6 gene mutations significantly increase hepatocellular carcinoma risk in Khyber Pakhtunkhwa. These findings highlight the genetic susceptibility associated with Interleukin-6 variants in liver cancer development.
Area of Science:
- Genetics
- Oncology
- Immunology
Background:
- Hepatocellular carcinoma (HCC) is a primary liver malignancy with multifactorial risk.
- Interleukin-6 (IL-6) is a key proinflammatory cytokine involved in immune responses and other vital functions.
Purpose of the Study:
- To investigate the association between specific Interleukin-6 gene mutations (rs2069837 and rs17147230) and the genetic risk of hepatocellular carcinoma.
- To evaluate the frequency of these IL-6 mutations in the Khyber Pakhtunkhwa population.
Main Methods:
- Genomic DNA was extracted from peripheral blood cells of 72 HCC cases and 38 controls.
- Interleukin-6 genotyping for rs2069837 and rs17147230 was performed using the T-ARMS-PCR technique.
Main Results:
- A significant increase in HCC risk was observed with heterozygous G allele (rs2069837) (OR=10.667, p<0.0001) and heterozygous T allele (rs17147230) (OR=75.385, p<0.0001).
- Under a recessive gene model, rs2069837 was insignificant (p=0.337), while rs17147230 showed significance (OR=0.298, p=0.0085).
Conclusions:
- Interleukin-6 gene mutations are associated with increased susceptibility to hepatocellular carcinoma.
- Further research involving other interleukins and whole gene sequencing is recommended to elucidate the role of IL-6 in HCC.
